Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,135.95
(
-0.04%
)
US TECH 100
26,588.31
(
1.09%
)
Dow Jones
48,861.81
(
-0.57%
)
Brent Oil
112.38
(
7.63%
)
Bitcoin
75,911.70
(
-0.57%
)
News Focus
News Focus
Post# of 257469
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122909
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 244643

Tuesday, 08/05/2025 1:03:31 PM

Tuesday, August 05, 2025 1:03:31 PM

Post# of 257469
YMAB acquired at $8.60/sh cash—a 105% premium to yesterday’s closing price:

https://www.globenewswire.com/news-release/2025/08/05/3127378/0/en/SERB-Pharmaceuticals-Agrees-to-Acquire-Y-mAbs-Therapeutics.html

The buyer is SERB Pharma, a private company based in Pennsylvania that specializes in drugs for emergency care. The nominal deal value is $412M.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today